Similar articles for PMID: 17873129

Year	Number of Results
2000	2
2002	1
2003	4
2004	9
2005	7
2006	8
2007	9
2008	9
2009	11
2010	12
2011	7
2012	9
2013	6
2014	11
2015	13
2016	8
2017	7
2018	9
2019	9
2020	7
2021	4
2022	2
2023	0

1

Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, Paone G, Talbot JN, Rahmouni A, Meignan M. Lin C, et al. J Nucl Med. 2007 Oct;48(10):1626-32. doi: 10.2967/jnumed.107.042093. Epub 2007 Sep 14. J Nucl Med. 2007. PMID: 17873129 Free article.

2

Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy.

Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, Haioun C, Meignan M. Itti E, et al. J Nucl Med. 2009 Apr;50(4):527-33. doi: 10.2967/jnumed.108.057703. Epub 2009 Mar 16. J Nucl Med. 2009. PMID: 19289424 Free article. Clinical Trial.

3

The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.

Lee HW, Lee HM, Choi SE, Yoo H, Ahn SG, Lee MK, Jeong J, Jung WH. Lee HW, et al. J Nucl Med. 2016 Aug;57(8):1183-8. doi: 10.2967/jnumed.115.166322. Epub 2016 Mar 31. J Nucl Med. 2016. PMID: 27033896 Free article.

4

Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.

Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A, Ohnuki T, Nishikawa T, Kusakabe K. Hashimoto Y, et al. J Nucl Med. 2006 Mar;47(3):426-31. J Nucl Med. 2006. PMID: 16513611 Free article.

5

Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.

Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, Chrétien ML, Bastie JN, Brunotte F, Casasnovas RO. Rossi C, et al. J Nucl Med. 2014 Apr;55(4):569-73. doi: 10.2967/jnumed.113.130609. Epub 2014 Feb 24. J Nucl Med. 2014. PMID: 24566003 Free article.

6

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.

Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. Cashen AF, et al. J Nucl Med. 2011 Mar;52(3):386-92. doi: 10.2967/jnumed.110.082586. Epub 2011 Feb 14. J Nucl Med. 2011. PMID: 21321279 Free PMC article.

7

Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.

Lee H, Kim SK, Kim YI, Kim TS, Kang SH, Park WS, Yun T, Eom HS. Lee H, et al. J Nucl Med. 2014 Feb;55(2):216-22. doi: 10.2967/jnumed.113.124172. Epub 2013 Dec 23. J Nucl Med. 2014. PMID: 24365650 Free article.

8

Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma.

Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, Lee MC, Lee DS. Lee JW, et al. J Nucl Med. 2009 May;50(5):682-7. doi: 10.2967/jnumed.108.060574. Epub 2009 Apr 16. J Nucl Med. 2009. PMID: 19372474 Free article. Clinical Trial.

9

18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.

Choi JY, Jang HJ, Shim YM, Kim K, Lee KS, Lee KH, Choi Y, Choe YS, Kim BT. Choi JY, et al. J Nucl Med. 2004 Nov;45(11):1843-50. J Nucl Med. 2004. PMID: 15534053 Free article. Clinical Trial.

10

Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.

Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, Gillham C, Reynolds JV. Malik V, et al. J Nucl Med. 2010 Dec;51(12):1863-9. doi: 10.2967/jnumed.110.079566. Epub 2010 Nov 15. J Nucl Med. 2010. PMID: 21078796 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed